NCT04595617View on ClinicalTrials.gov

Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Glanzmann Thrombasthenia
Interventions
BIOLOGICAL

Antibodies screening

All included GT patients will be enrolled from different national centres during a 6 months period. Antibodies screening will be systematically realized every six months (+/- 2 weeks) and after each last blood transfusion at 7-10 days and one month (+/- 2 weeks), during a period of 18 months.

Trial Locations (7)

Unknown

CHU Bordeaux - Hôpital Haut-Lévêque, Bordeaux

CHU Bordeaux - Hôpital Pellegrin, Bordeaux

Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre

Hôpital la Timone, APHM, Marseille

CHU Nîmes, Nîmes

CHU Strasbourg, Strasbourg

CHU Toulouse, Toulouse

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT04595617 - Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) | Biotech Hunter | Biotech Hunter